D. Siegel

D. Siegel, D. Vesole, A. Goy, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma

D. Siegel, N. Raje, T. Kovacsovics, 2020, American journal of hematology.

M. Dimopoulos, A. Palumbo, A. Jakubowiak, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Michael L. Wang, D. Siegel, R. Orlowski, 2013, Blood.

Biology and treatment of multiple myeloma.

D. Siegel, J. Michaeli, R. Niesvizky, 1993, Blood reviews.

Modulation of lymphocyte proliferation and immunoglobulin synthesis by interferon-gamma and "type I" interferons.

D. Siegel, J. Vilček, J. Le, 1986, Cellular immunology.

Oligoclonal Protein Bands and Ig Isotype Switching in Multiple Myeloma Treated With High-Dose Therapy and Hematopoietic Cell Transplantation

B. Barlogie, S. Jagannath, D. Siegel, 1998 .

Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma

D. Siegel, R. Feinman, R. Korngold, 2021, American journal of hematology.

A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma

D. Siegel, D. Vesole, A. Pecora, 2019, Bone Marrow Transplantation.

A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

D. Siegel, D. Vesole, A. Pecora, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2016, Blood.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2013, Leukemia.

From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma

D. Siegel, 2013, Therapeutic advances in hematology.

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis

M. Dimopoulos, D. Siegel, P. Richardson, 2017, European journal of haematology.

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

A. Palumbo, A. Jakubowiak, D. Siegel, 2017, Blood Cancer Journal.

Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.

D. Siegel, D. Vesole, A. McNeill, 2012, Clinical lymphoma, myeloma & leukemia.

Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi

M. Williams, R. Fonseca, D. Siegel, 2008 .

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial

D. Siegel, P. Hari, A. Nooka, 2021, EJHaem.

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

D. Auclair, R. Fonseca, S. Jagannath, 2017, Clinical lymphoma, myeloma & leukemia.

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.

M. Dimopoulos, D. Siegel, H. Ludwig, 2019, Blood.

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

S. Jagannath, D. Siegel, F. Petrocca, 2018, Blood.

A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use

S. Jagannath, D. Siegel, R. Vij, 2015, CPT: pharmacometrics & systems pharmacology.

Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial

R. Fonseca, D. Siegel, S. Rajkumar, 2010 .

Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.

D. Siegel, D. Vesole, S. Goldberg, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stem cell transplantation for multiple myeloma-10 years later

B. Barlogie, S. Jagannath, D. Siegel, 2000 .

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

D. Auclair, D. Siegel, J. Kaufman, 2018, Blood.

Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma

D. Siegel, W. Pierceall, P. Neri, 2020, Clinical Cancer Research.

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

S. Jagannath, D. Siegel, R. Vij, 2018, British journal of haematology.

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

D. Siegel, N. Munshi, D. Reece, 2019, British journal of haematology.

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

G. Ahmann, R. Fonseca, S. Jagannath, 2016 .

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

A. Azmi, C. Hofmeister, D. Siegel, 2014 .

Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced IL-6 and IL-10 production

D. Siegel, J. Zilberberg, Woo Y. Lee, 2022, Heliyon.

Myc/max family of transcription factors and bcl-2 are involved in drug-induced apoptosis of myeloma cells.

B. Barlogie, D. Siegel, J. Epstein, 1997, Current topics in microbiology and immunology.

Immune tolerance with combined allogeneic haplo‐identical haematopoietic stem cell transplant and renal transplant

D. Siegel, M. Donato, S. Rowley, 2021, British journal of haematology.

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

D. Siegel, D. Vesole, A. Mato, 2015, British journal of haematology.

Interferon-γ enhances target cell sensitivity to monocyte killing

D. Siegel, J. Vilček, R. Feinman, 1986 .

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

H. Goldschmidt, D. Siegel, P. Hari, 2017, Leukemia.

A phase 2 study of single-agent carﬁlzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

D. Siegel, P. Richardson, C. Mitsiades, 2008 .

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.

D. Siegel, K. Papadopoulos, S. Rosen, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2015, Leukemia & lymphoma.

Reply to “The challenge of cross-trial comparison using limited data” Haematologica. 2014;99(8):e000

D. Siegel, 2014, Haematologica.

Carfilzomib—A Selective Proteasome Inhibitor for the Treatment of Relapsed and/or Refractory Multiple Myeloma

D. Siegel, R. Vij, R. Niesvizky, 2012 .

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma: Updated Efficacy and Tolerability From the Completed 20/56mg/m2 Expansion Cohort of PX-171-007

D. Siegel, S. Singhal, K. Papadopoulos, 2011 .

Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib

M. Buyse, D. Siegel, R. Vij, 2011 .

Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

S. Jagannath, D. Siegel, R. Vij, 2010 .

Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

H. Goldschmidt, M. Dimopoulos, A. Jakubowiak, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The forgotten class of drugs for multiple myeloma: HDAC inhibitors.

D. Siegel, D. Vesole, N. Biran, 2018, The Lancet. Haematology.

A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide‐containing regimens

D. Siegel, D. Vesole, L. Sanchez, 2017, British journal of haematology.

Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.

D. Siegel, D. Vesole, A. Mato, 2016, Clinical lymphoma, myeloma & leukemia.

Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience

S. Jagannath, D. Siegel, V. Richon, 2008 .

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

J. Byrd, G. Pond, A. Oza, 2013 .

Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

J. Byrd, G. Pond, A. Oza, 2013 .

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

J. Byrd, G. Pond, A. Oza, 2013 .

A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

D. Siegel, J. Miguel, M. Dolled-Filhart, 2014 .

Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial

Linda Z Sun, H. Goldschmidt, M. Dimopoulos, 2011 .

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia

A. Jakubowiak, D. Siegel, R. Vij, 2019, Clinical Cancer Research.

Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model

S. Jagannath, D. Siegel, D. Globe, 2016, Journal of managed care & specialty pharmacy.

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

S. Jagannath, D. Siegel, D. Globe, 2015, American health & drug benefits.

Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM).

S. Jagannath, A. Jakubowiak, D. Siegel, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

H. Goldschmidt, M. Dimopoulos, S. Jagannath, 2016, Clinical lymphoma, myeloma & leukemia.

Regulation of IFN-gamma induction in human peripheral blood cells by exogenous and endogenously produced interleukin 2.

D. Siegel, J. Vilček, D. Henriksen-DeStefano, 1985, Journal of immunology.

Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study

H. Goldschmidt, M. Dimopoulos, D. Siegel, 2018, Blood.

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

D. Siegel, W. Pierceall, S. Srinivasan, 2019, British journal of haematology.

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

D. Siegel, D. Vesole, Jaeil Ahn, 2022, Blood Cancer Journal.

Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

S. Jagannath, D. Siegel, Chiung-Yu Huang, 2021, Cancer.

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

D. Siegel, W. Pierceall, D. Reece, 2020, Leukemia.

Safety and tolerability of vorinostat—Experience from the vorinostat clinical trial program

D. Siegel, J. Wigginton, C. Belani, 2008 .

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, S. Lonial, 2012, Clinical lymphoma, myeloma & leukemia.

Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience

B. Barlogie, S. Jagannath, D. Siegel, 2003, British journal of haematology.

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, D. Siegel, P. Richardson, 2014, Blood Cancer Journal.

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, D. Siegel, P. Richardson, 2014, Blood Cancer Journal.

Inaccuracies in 24-Hour Urine Testing for Monoclonal Gammopathies Serum Free Light Chain Analysis Provides a More Accurate Measure of Light Chain Burden Than Urine Protein Electrophoresis

D. Siegel, A. McNeill, N. Lendvai, 2009 .

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

D. Esseltine, B. Barlogie, P. Wen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

P. Fine, D. Siegel, V. D’Agati, 2003, Kidney international.

Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells (HSC) Used in Salvage Autologous Stem Cell Transplantation: Prolonged Storage of HSCs Sustains Hematological Reconstitution Potential.

D. Siegel, D. Vesole, M. Donato, 2022, Transplantation and cellular therapy.

Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series.

D. Siegel, P. Richardson, N. Callander, 2016, Clinical lymphoma, myeloma & leukemia.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

H. Goldschmidt, G. Morgan, A. Palumbo, 2012, Leukemia.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

H. Goldschmidt, G. Morgan, A. Palumbo, 2012, Leukemia.

TAK‐228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia

R. Neuwirth, D. Siegel, R. Vij, 2016, American journal of hematology.

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

R. Fonseca, D. Siegel, S. Rajkumar, 2010, The Lancet. Oncology.

Regulation of NF-kB in multiple myeloma: therapeutic implications.

D. Siegel, R. Feinman, David S Siegel, 2004, Clinical advances in hematology & oncology : H&O.

Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.

R. Advani, D. Siegel, D. Juric, 2022, Journal of Clinical Oncology.

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

D. Siegel, Jaeil Ahn, A. Goy, 2020, The Lancet Rheumatology.

Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2007, British journal of haematology.

Identification of New Nonrandom Translocations in Multiple Myeloma With Multicolor Spectral Karyotyping

B. Barlogie, J. Shaughnessy, D. Siegel, 1998 .

Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.

B. Barlogie, D. Siegel, J. Epstein, 1999, Blood.

Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015, The New England journal of medicine.

Glucocorticoid-Induced Apoptosis by Bcl-2 B in the Rescue of Multiple Myeloma Cells From κ Role of NF-

B. Barlogie, D. Siegel, J. Epstein, 2013 .

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

P. Sonneveld, A. Jakubowiak, D. Siegel, 2019, Leukemia.

in the context of global gene expression survival in multiple myeloma treated with Total Therapy I: interpretation especially of chromosome 13 and hypodiploidy, ensures long-term Continuous absence of metaphase-defined cytogenetic abnormalities,

B. Barlogie, J. Shaughnessy, S. Jagannath, 2013 .

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.

F. Zhan, B. Barlogie, J. Shaughnessy, 2003, Blood.

Age is not a prognostic variable with autotransplants for multiple myeloma.

B. Barlogie, D. Siegel, S. Singhal, 1999, Blood.

Multicolor Spectral Karyotyping Identification of New Nonrandom Translocations in Multiple Myeloma With

B. Barlogie, J. Shaughnessy, D. Siegel, 2011 .

An unusual finding in the renal medulla.

D. Siegel, V. D’Agati, G. Bhagat, 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

KIDNEY BIOPSY TEACHING CASE An Unusual Finding in the Renal Medulla

D. Siegel, G. Bhagat, G. Markowitz, 2005 .

Erratum: Antitumor activity of thalidomide in refractory multiple myeloma (New England Journal of Medicine (November 18, 1999) 341 (1565-1571))

B. Barlogie, D. Siegel, N. Munshi, 2000 .

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

D. Siegel, D. Vesole, A. Goy, 2019, Blood.

Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells.

D. Siegel, J. Michaeli, P. Marks, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

M. Dimopoulos, D. Siegel, R. Hájek, 2018, Blood.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

S. Jagannath, S. Lonial, D. Siegel, 2013, Haematologica.

Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.

D. Siegel, 2012, Seminars in hematology.

Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations

B. Barlogie, D. Siegel, R. Desikan, 2002, British journal of haematology.

Subepithelial corneal immunoglobulin deposition as a manifestation of multiple myeloma: a case report and literature review.

D. Siegel, D. Vesole, J. Richter, 2014, Clinical lymphoma, myeloma & leukemia.

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

H. Goldschmidt, S. Jagannath, D. Siegel, 2021, Blood Cancer Journal.

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

D. Siegel, D. Reece, A. Agarwal, 2020 .

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

M. Dimopoulos, D. Siegel, A. Oriol, 2020 .

Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.

D. Siegel, D. Reece, G. Schiller, 2018 .

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

C. Hofmeister, S. Lonial, D. Siegel, 2017, Leukemia.

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

M. Dimopoulos, P. Sonneveld, D. Siegel, 2017, Clinical pharmacology : advances and applications.

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

H. Goldschmidt, M. Dimopoulos, S. Jagannath, 2016, Leukemia & lymphoma.

Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment

M. Dimopoulos, D. Siegel, J. Miguel, 2015 .

Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors.

M. Dimopoulos, A. Palumbo, P. Sonneveld, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.

M. Dimopoulos, D. Siegel, J. Zeldis, 2011, Clinical lymphoma, myeloma & leukemia.

Liquid tumors in the elderly.

D. Siegel, A. Goy, A. Mato, 2012, Clinics in geriatric medicine.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

A. Jakubowiak, D. Siegel, T. Zimmerman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.

S. Jagannath, D. Siegel, N. Munshi, 2018 .

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

S. Jagannath, S. Lonial, D. Siegel, 2020 .

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

S. Jagannath, D. Siegel, N. Munshi, 2019, Blood.

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

A. Jakubowiak, D. Siegel, J. Kaufman, 2020 .

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis

H. Einsele, S. Jagannath, D. Siegel, 2020, Transplantation and Cellular Therapy.

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, D. Siegel, 2021, Blood.

KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.

H. Goldschmidt, S. Jagannath, D. Siegel, 2020 .

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

M. Dimopoulos, D. Siegel, X. Leleu, 2019 .

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013

D. Siegel, R. Vij, T. Wise-Draper, 2019, British journal of haematology.

Impact of Early Response to Sequential High-dose Chemotherapy on Outcome of Patients With Advanced Myeloma and Poor Prognostic Features

D. Siegel, J. Michaeli, J. Glassman, 2002, Leukemia & lymphoma.

Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma

B. Barlogie, D. Siegel, S. Singhal, 1999 .

Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series

D. Siegel, D. Vesole, J. Richter, 2018, Leukemia & lymphoma.

Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)

D. Siegel, S. Treon, N. Raje, 2014 .

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

R. Fonseca, D. Siegel, S. Rajkumar, 2006 .

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.

M. Dimopoulos, D. Siegel, Shaji K. Kumar, 2020, Blood advances.

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

M. Dimopoulos, D. Siegel, R. Hájek, 2020, Blood Cancer Journal.

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up

R. Fonseca, D. Siegel, S. Rajkumar, 2016, Blood Cancer Journal.

Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

S. Jagannath, S. Lonial, D. Siegel, 2014 .

Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

Michael L. Wang, D. Siegel, R. Orlowski, 2013, Clinical Cancer Research.

An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, British journal of haematology.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Impact of high‐risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03

H. Uno, G. Ahmann, R. Fonseca, 2011, British journal of haematology.

Hypercalcaemia and increased serum interleukin‐6 levels induced by all‐trans retinoic acid in patients with multiple myeloma

D. Siegel, R. Warrell, J. Michaeli, 1995, British journal of haematology.

Extended Survival in Advanced-Stage Multiple Myeloma Patients Treated with Gallium Nitrate

D. Siegel, J. Michaeli, R. Niesvizky, 2002, Leukemia & lymphoma.

Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)

R. Fonseca, D. Siegel, S. Rajkumar, 2010 .

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial

D. Siegel, D. Reece, A. Agarwal, 2022, Leukemia & lymphoma.

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

M. Dimopoulos, D. Siegel, A. Oriol, 2020, Leukemia & lymphoma.

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

M. Dimopoulos, D. Siegel, M. Mateos, 2018, Blood.

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

D. Siegel, D. Reece, A. Agarwal, 2018, Blood.

Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).

S. Jagannath, D. Siegel, R. Vij, 2012 .

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

S. Jagannath, A. Jakubowiak, D. Siegel, 2014 .

Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.

D. Siegel, J. Miguel, N. Munshi, 2016 .

Interim Analysis Of The Mmrf Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles

Winnie S. Liang, J. Carpten, S. Jewell, 2013 .

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

P. Sonneveld, S. Jagannath, S. Lonial, 2020 .

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

S. Jagannath, D. Siegel, P. Hari, 2021, Blood.

Risk Adapted Dose Intensive DICEP Salvage Chemotherapy Prior to Autologous Stem Cell Transplantation Yields Successful Outcomes in Chemotherapy Refractory Lymphoma.

D. Siegel, A. Pecora, S. Goldberg, 2004 .

A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma.

D. Siegel, P. Richardson, O. Sezer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Linda Z Sun, D. Siegel, P. Richardson, 2007 .

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

S. Jagannath, A. Jakubowiak, D. Siegel, 2020 .

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

S. Jagannath, D. Siegel, N. Munshi, 2020 .

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.

S. Jagannath, S. Lonial, D. Siegel, 2021, The Lancet. Haematology.

PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update.

S. Jagannath, D. Siegel, R. Vij, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1b Dose-Escalation Study of Split-Dose Oprozomib (ONX0912) in Patients with Hematologic Malignancies

D. Siegel, M. Savona, J. Berdeja, 2012 .

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

S. Jagannath, S. Lonial, D. Siegel, 2013 .

Patient-specific 3D microfluidic tissue model for multiple myeloma.

D. Siegel, P. Tolias, J. Zilberberg, 2014, Tissue engineering. Part C, Methods.

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

S. Jagannath, S. Lonial, D. Siegel, 2021 .

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

H. Goldschmidt, S. Jagannath, S. Lonial, 2020 .

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

P. Sonneveld, S. Jagannath, S. Lonial, 2019, Blood.

Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).

M. Dimopoulos, K. Anderson, S. Jagannath, 2010 .

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

D. Siegel, R. Feinman, D. Vesole, 2019, Blood.

A242 Vorinostat and Bortezomib in Relapsed/Refractory MM

S. Jagannath, D. Siegel, V. Richon, 2009 .

A241 Vorinostat/Lenalidomide/Dexamethasone: A Phase I Study

D. Siegel, P. Richardson, C. Mitsiades, 2009 .

Pretransplant induction regimens for multiple myeloma.

D. Siegel, D. Vesole, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study

Winnie S. Liang, J. Carpten, S. Jewell, 2021, medRxiv.

Emerging Treatment Options for Relapsed and Refractory Multiple Myeloma

D. Siegel, R. Vij, 2013 .

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

D. Siegel, W. Pierceall, D. Reece, 2018, Blood.

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

D. Siegel, M. Atkins, R. Feinman, 2018, Blood.

Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.

D. Siegel, N. Raje, T. Kovacsovics, 2018 .

Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).

M. Dimopoulos, A. Jakubowiak, D. Siegel, 2016 .

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.

H. Goldschmidt, G. Morgan, P. Sonneveld, 2009 .

Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma

S. Jagannath, S. Lonial, D. Siegel, 2016 .

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

S. Jagannath, S. Lonial, D. Siegel, 2012 .

Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Michael L. Wang, S. Jagannath, D. Siegel, 2008 .

Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

S. Jagannath, A. Jakubowiak, D. Siegel, 2008 .

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

M. Dimopoulos, D. Siegel, P. Richardson, 2010 .

Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.

K. Anderson, A. Jakubowiak, D. Siegel, 2010 .

Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).

M. Dimopoulos, K. Anderson, D. Siegel, 2010 .

Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials

M. Dimopoulos, D. Siegel, R. Orlowski, 2020, Cancer medicine.

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

M. Dimopoulos, D. Siegel, R. Hájek, 2020, Blood Cancer Journal.

The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials,

A. Jakubowiak, D. Siegel, R. Vij, 2011 .

OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa

H. Goldschmidt, H. Einsele, S. Jagannath, 2021, Clinical Lymphoma Myeloma and Leukemia.

Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma

E. Sausville, D. Siegel, S. Singhal, 2010 .

Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

K. Anderson, D. Siegel, O. Sezer, 2010 .

Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

D. Siegel, J. H. Lee, R. Hájek, 2017 .

Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies

A. Jakubowiak, D. Siegel, R. Vij, 2016 .

First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

D. Siegel, A. Chanan-Khan, J. Kaufman, 2008 .

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

D. Siegel, E. Ostertag, A. Deol, 2021, Blood.

Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

S. Jagannath, S. Lonial, D. Siegel, 2020, American journal of hematology.

P-279: Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial

S. Lonial, D. Siegel, P. Maciag, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.

Hajime Uno, Rafael Fonseca, H. Uno, 2011, Blood.

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

S. Jagannath, S. Lonial, D. Siegel, 2019, Blood.

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment

S. Lonial, D. Siegel, R. Harvey, 2013 .

Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.

C. Hofmeister, S. Jagannath, S. Lonial, 2013 .

Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma.

D. Siegel, D. Vesole, A. Pecora, 2020, Clinical lymphoma, myeloma & leukemia.

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

Linda Z Sun, H. Goldschmidt, M. Dimopoulos, 2011 .

A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma

D. Siegel, K. Papadopoulos, A. Badros, 2012 .

Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Patient‐reported outcomes following autologous stem cell transplant for patients with multiple myeloma

D. Siegel, A. Potosky, D. Vesole, 2021, EJHaem.

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).

M. Dimopoulos, A. Jakubowiak, D. Siegel, 2015 .

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study

D. Auclair, A. Jakubowiak, D. Siegel, 2018, Blood.

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

D. Siegel, M. Atkins, R. Feinman, 2018, Blood.

MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).

D. Siegel, M. Zaki, J. Shah, 2013 .

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis

C. Hofmeister, S. Jagannath, S. Lonial, 2012 .

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2004, British journal of haematology.

Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.

B. Barlogie, S. Jagannath, D. Siegel, 1998, Blood.

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).

A. Jakubowiak, D. Siegel, P. Moreau, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.

S. Jagannath, A. Jakubowiak, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM).

D. Siegel, S. Singhal, P. Hari, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1999, Blood.

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

E Terpos, M. Beksac, M. Dimopoulos, 2009, Leukemia.

Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.

B. Barlogie, S. Jagannath, D. Siegel, 1997, Leukemia & lymphoma.

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

D. Siegel, R. Vij, J. Kaufman, 2013 .

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes

D. Siegel, P. Richardson, M. Zaki, 2012 .

Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma,

D. Siegel, D. Vesole, J. Richter, 2011 .

Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.

B. Barlogie, S. Jagannath, D. Siegel, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).

S. Jagannath, D. Siegel, S. Kanner, 2023, Journal of Clinical Oncology.

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Blood.

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

B. Barlogie, S. Jagannath, S. Lonial, 2006 .

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

D. Siegel, M. Liedtke, F. Petrocca, 2023, Nature Medicine.

Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States

D. Auclair, D. Siegel, J. Kaufman, 2022, Patient preference and adherence.

PPA_A_345906 573..585

D. Auclair, D. Siegel, J. Kaufman, 2022 .

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

B. Barlogie, J. Shaughnessy, R. Fonseca, 2010, Mayo Clinic proceedings.

MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).

C. Hofmeister, S. Lonial, D. Siegel, 2013 .

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.

B. Barlogie, S. Jagannath, D. Siegel, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL).

D. Siegel, A. Goy, A. Mato, 2010 .

The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.

D. Siegel, D. Vesole, A. Goy, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma

A. Jakubowiak, D. Siegel, S. Trudel, 2019, Clinical Lymphoma Myeloma and Leukemia.

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

M. Dimopoulos, D. Siegel, X. Leleu, 2023, Blood advances.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

S. Jagannath, S. Lonial, D. Siegel, 2013, Haematologica.

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure

C. Hofmeister, S. Jagannath, D. Siegel, 2012 .

Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT

A. Jakubowiak, D. Siegel, P. Richardson, 2012 .

A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials.

Michael L. Wang, D. Siegel, R. Vij, 2012 .